- Home
- IBRX vs SYRE Comparison
IBRX vs SYRE Comparison
Compare IBRX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | SYRE |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.5B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IBRX | SYRE |
|---|---|---|
| Price | $7.35 | $101.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $12.57 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 11.7M | 1.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | N/A |
| Revenue Next Year | $131.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $14.49 |
| 52 Week High | $12.43 | $101.71 |
Technical Indicators
Market Signals| Indicator | IBRX | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 78.20 |
| Support Level | $6.69 | $66.78 |
| Resistance Level | $8.54 | N/A |
| Average True Range (ATR) | 0.40 | 5.21 |
| MACD | 0.04 | 2.33 |
| Stochastic Oscillator | 89.02 | 96.11 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.